Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13172MR)

This product GTTS-WQ13172MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Acute myeloid leukemia (AML), Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13172MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7329MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ5847MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ5326MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ2808MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ14224MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ9193MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ8542MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ9738MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JR-141
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW